还原叶酸载体基因多态性与大剂量甲氨蝶呤药物不良反应关系的Meta分析  

Meta-analysis of association between reduced folate carrier G80A genetic polymorphism and high- dose methotrexate toxicity

作　　者：顾平 刘易陇 何霞[2] 童荣生[1,2] 

机构地区：[1]西南医科大学药学院,四川泸州646000 [2]四川省医学科学院.四川省人民医院药学部,成都610072

出　　处：《中国临床药理学杂志》2016年第15期1432-1434,共3页The Chinese Journal of Clinical Pharmacology

基　　金：四川省科技基础条件平台基金资助项目(14010159;12010147)

摘　　要：目的探讨中国人群还原叶酸载体基因RFC1 G80A基因多态性与大剂量甲氨蝶呤化疗药物不良反应的关系。方法检索中国人群RFC1 G80A基因多态性与大剂量甲氨蝶呤药物不良反应相关性的研究,对符合标准的临床研究进行资料提取,运用Stata12.0统计软件进行Meta分析,比较不同RFC1 G80A基因型(AA vs GG+GA)患者的药物不良反应发生情况。结果共纳入8篇文献。Meta分析显示:中国人群RFC1 G80A AA型肝功能损伤、肾功能损伤和消化道反应均高于GG+GA型(P<0.05),儿童患者AA型骨髓抑制高于GG+GA型(P<0.05)。结论 RFC1 G80A基因多态性与大剂量甲氨蝶呤药物不良反应存在相关性,但仍需要更多大样本的临床研究来进行验证。Objective To investigate the relationship between reduced folate carrier G80A （RFC1 GSOA） genetic polymorphism and high -dose methotrexate toxicity in China. Methods The relevant data bases were searched and reviewed. Meta - analysis was performed by Stata12.0. Results Eight studies were included. The Meta- analysis showed that there were significantly increased risk of liver toxicity, renal toxicity, gastrointestinal toxicity in RFC1 GSOA AA compared to GG ＋ GA （P 〈 0. 05 ）. There was also a significantly increased risk of myelosup- pressionin children with RFC1 G80A AA compared to GG ＋ GA （P 〈 0. 05 ）. Conclusion RFC1 GSOA genetic polymorphism was associated with the high - dose methotrexate toxicity. However, further studies with larger data are required to validate our findings.

关 键 词：还原叶酸载体 基因多态性 甲氨蝶呤 META分析 

分 类 号：R979.1[医药卫生—药品]